Ignet

Gene Information

Gene symbol: IGHV

Gene name: immunoglobulin heavy variable group

HGNC ID: 5545

Related Genes

#	Gene Symbol	Number of hits
1	BCL6	1 hits
2	BCR	1 hits
3	CD27	1 hits
4	IGHV1-69	1 hits
5	IGHV6-1	1 hits
6	IGKV	1 hits
7	IGLV	1 hits
8	IL2	1 hits

Related Sentences

#	PMID	Sentence
1	12513814	The gene fragments of the IgH variable region (IgHV), which were obtained from the genomic DNA and RNA of Namalwa cell respectively, were cloned into the eukaryocytic expression vector pcDNA 3.0 to be used as the idiotypic nucleic acid vaccines.
2	17204185	[Construction of fusion gene between IgGHV and IL-2 as IgHV nucleic acid vaccine against lymphoma].
3	17204185	The purpose of this study was to construct the IgHV and IL-2 coexpressed vector.
4	17204185	Meanwhile, the gene fragments of IgHV linked with gene of IL-2 were inserted into pcDNA3.0 to form a fusion gene of IgHV-IL-2.
5	17204185	The 3' end of IgHV was linked to IL-2 gene, and IL-2 could be correctly expressed.
6	17204185	[Construction of fusion gene between IgGHV and IL-2 as IgHV nucleic acid vaccine against lymphoma].
7	17204185	The purpose of this study was to construct the IgHV and IL-2 coexpressed vector.
8	17204185	Meanwhile, the gene fragments of IgHV linked with gene of IL-2 were inserted into pcDNA3.0 to form a fusion gene of IgHV-IL-2.
9	17204185	The 3' end of IgHV was linked to IL-2 gene, and IL-2 could be correctly expressed.
10	17204185	[Construction of fusion gene between IgGHV and IL-2 as IgHV nucleic acid vaccine against lymphoma].
11	17204185	The purpose of this study was to construct the IgHV and IL-2 coexpressed vector.
12	17204185	Meanwhile, the gene fragments of IgHV linked with gene of IL-2 were inserted into pcDNA3.0 to form a fusion gene of IgHV-IL-2.
13	17204185	The 3' end of IgHV was linked to IL-2 gene, and IL-2 could be correctly expressed.
14	17204185	[Construction of fusion gene between IgGHV and IL-2 as IgHV nucleic acid vaccine against lymphoma].
15	17204185	The purpose of this study was to construct the IgHV and IL-2 coexpressed vector.
16	17204185	Meanwhile, the gene fragments of IgHV linked with gene of IL-2 were inserted into pcDNA3.0 to form a fusion gene of IgHV-IL-2.
17	17204185	The 3' end of IgHV was linked to IL-2 gene, and IL-2 could be correctly expressed.
18	17983446	The clones expressing IGHV1-69 and IGHV 3-21 provided significant passive protection against invasive pneumococcal disease in vivo.
19	24614505	B-cell chronic lymphocytic leukemia (B-CLL) patients expressing unmutated immunoglobulin heavy variable regions (IGHVs) use the IGHV1-69 B cell receptor (BCR) in 25% of cases.
20	24614505	To test this hypothesis, we rescued 5 IGHV1-69 unmutated antibodies as heterohybridoma IgM paraproteins and as recombinant IgG1 antibodies from B-CLL patients, determined their antigenic specificities and analyzed BCR sequences.
21	24614505	IGHV1-69 B-CLL antibodies were enriched for reactivity with HIV-1 envelope gp41, influenza, hepatitis C virus E2 protein and intestinal commensal bacteria.
22	24614505	These IGHV1-69 B-CLL antibodies preferentially used IGHD3 and IGHJ6 gene segments and had long heavy chain complementary determining region 3s (HCDR3s) (≥21 aa).
23	24614505	IGHV1-69 B-CLL BCRs exhibited a phenylalanine at position 54 (F54) of the HCDR2 as do rare HIV-1 gp41 and influenza hemagglutinin stem neutralizing antibodies, while IGHV1-69 gp41 antibodies induced by HIV-1 infection predominantly used leucine (L54) allelic variants.
24	24965774	Sequencing of IGHV, IGLV, IGKV, and BCL6 genes from these D-specific B cell clones demonstrated that both CD27(-)IgM(+) and CD27(+)IgM(+) B cells harbored somatic mutations, documenting their Ag-selected nature.
25	25996084	A sorting strategy was developed using a panel of molecular markers (CD3, CD19, CD20, surface IgG, intracellular IgG, CD27, Ki67 and CD38) to identify the kinetics of B cell response after vaccination.
26	25996084	Sequence analysis revealed that diverse IGHV subgroups (for VH) and IGKV and IGLV subgroups (for VL) were represented in the cloned antibodies.